Skip to main content
Top
Published in: Esophagus 1/2022

01-01-2022 | Esophageal Cancer | Original Article

Nationwide survey of the follow-up practices for patients with esophageal carcinoma after radical treatment: historical changes and future perspectives in Japan

Authors: Tomonori Nakanoko, Masaru Morita, Yuichiro Nakashima, Mitsuhiko Ota, Masahiko Ikebe, Manabu Yamamoto, Eisuke Booka, Hiroya Takeuchi, Yuko Kitagawa, Hisahiro Matsubara, Yuichiro Doki, Yasushi Toh

Published in: Esophagus | Issue 1/2022

Login to get access

Abstract

Background

No post-treatment follow-up methods have been established yet for patients with esophageal carcinoma who undergo radical esophagectomy (Surg) or who show complete response to definitive chemoradiotherapy (dCRT-CR). The purpose of this study was to investigate the current status of follow-up of the Surg and dCRT-CR patients in Japan, and understand the current reality and problems to establish an optimal follow-up method.

Methods

A questionnaire on the follow-up method adopted was sent by e-mail to 124 institutions approved by the Japan Esophageal Society as training institutions for board-certified esophageal surgeons; responses were received from 89 institutions. The data were compared with those obtained by a similar survey conducted in 2014.

Results

Follow-up methods markedly varied among institutions. Almost all institutions scheduled computed tomography and upper gastrointestinal endoscopy at least once a year up to postoperative year 5 for both the Surg and dCRT-CR groups. At least 70% of the institutions continued follow-up up to postoperative year 10, and this proportion had increased as compared to that reported from the 2014 survey. Only 25–30% of the institutions scheduled follow-up screening for metachronous head and neck cancer for both groups, and the health-related quality of life (HR-QOL) after the treatment were seldom assessed. These trends remained unchanged as compared to those reported from the 2014 survey.

Conclusions

The results suggest that the consensus of follow-up protocol could not be established. More attention is required for detection of metachronous cancers and assessment of the HR-QOL. Establishment of a consensus-based follow-up system and verification of its effectiveness are required.
Appendix
Available only for authorised users
Literature
1.
go back to reference NCCN Guidelines Version 5. 2020, Esophageal and Esophagogastric Junction Cancers. 2020 NCCN Guidelines Version 5. 2020, Esophageal and Esophagogastric Junction Cancers. 2020
2.
go back to reference Lordick F, Mariette C, Haustermans K, ESMO Guidelines Committee, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2016;27(suppl 5):v50–7.CrossRef Lordick F, Mariette C, Haustermans K, ESMO Guidelines Committee, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2016;27(suppl 5):v50–7.CrossRef
3.
go back to reference Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25–43.CrossRef Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25–43.CrossRef
4.
go back to reference Toh Y, Kitagawa Y, Kuwano H, et al. A nation-wide survey of follow-up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan. Esophagus. 2016;13:173–81.CrossRef Toh Y, Kitagawa Y, Kuwano H, et al. A nation-wide survey of follow-up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan. Esophagus. 2016;13:173–81.CrossRef
5.
go back to reference Inomata M, Shiroshita H, Uchida H, et al. Current status of endoscopic surgery in Japan: the 14th National Survey of Endoscopic Surgery by the Japan Society for Endoscopic Surgery. Asian J Endosc Surg. 2020;13:7–18.CrossRef Inomata M, Shiroshita H, Uchida H, et al. Current status of endoscopic surgery in Japan: the 14th National Survey of Endoscopic Surgery by the Japan Society for Endoscopic Surgery. Asian J Endosc Surg. 2020;13:7–18.CrossRef
6.
go back to reference Numasaki H, Teshima T, Okuda Y, Japanese Society for Radiation Oncology Database Committee, et al. Japanese structure survey of radiation oncology in 2013. J Radiat Res. 2020;61:799–816.CrossRef Numasaki H, Teshima T, Okuda Y, Japanese Society for Radiation Oncology Database Committee, et al. Japanese structure survey of radiation oncology in 2013. J Radiat Res. 2020;61:799–816.CrossRef
7.
go back to reference Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2008. Esophagus. 2015;12:130–57.CrossRef Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2008. Esophagus. 2015;12:130–57.CrossRef
8.
go back to reference Watanabe M, Tachimori Y, Oyama T, et al. Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus. 2021;18:1–24.CrossRef Watanabe M, Tachimori Y, Oyama T, et al. Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus. 2021;18:1–24.CrossRef
9.
go back to reference Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.CrossRef Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.CrossRef
10.
go back to reference Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part ii and III. Esophagus. 2017;14:37–65.CrossRef Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part ii and III. Esophagus. 2017;14:37–65.CrossRef
12.
go back to reference Lou F, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol. 2013;8:1558–62.CrossRef Lou F, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol. 2013;8:1558–62.CrossRef
13.
go back to reference Yamashita K, Watanabe M, Mine S, et al. Patterns and outcomes of recurrent esophageal cancer after curative esophagectomy. World J Surg. 2017;41:2337–44.CrossRef Yamashita K, Watanabe M, Mine S, et al. Patterns and outcomes of recurrent esophageal cancer after curative esophagectomy. World J Surg. 2017;41:2337–44.CrossRef
14.
go back to reference Steffen T, Dietrich D, Schnider A, Swiss Group for Clinical Cancer Research (SAKK), et al. Recurrence patterns and long-term results after induction chemotherapy, chemoradiotherapy, and curative surgery in patients with locally advanced esophageal cancer. Ann Surg. 2019;269:83–7.CrossRef Steffen T, Dietrich D, Schnider A, Swiss Group for Clinical Cancer Research (SAKK), et al. Recurrence patterns and long-term results after induction chemotherapy, chemoradiotherapy, and curative surgery in patients with locally advanced esophageal cancer. Ann Surg. 2019;269:83–7.CrossRef
15.
go back to reference Xi M, Xu C, Liao Z, et al. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017;124:318–24.CrossRef Xi M, Xu C, Liao Z, et al. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017;124:318–24.CrossRef
16.
go back to reference Schizas D, Lazaridis II, Moris D, et al. The role of surgical treatment in isolated organ recurrence of esophageal cancer—a systematic review of the literature. World J Surg Oncol. 2018;16:55.CrossRef Schizas D, Lazaridis II, Moris D, et al. The role of surgical treatment in isolated organ recurrence of esophageal cancer—a systematic review of the literature. World J Surg Oncol. 2018;16:55.CrossRef
17.
go back to reference Schizas D, Mylonas KS, Kapsampelis P, et al. Patients undergoing surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data. Interact Cardiovasc Thorac Surg. 2020;31:299–304.CrossRef Schizas D, Mylonas KS, Kapsampelis P, et al. Patients undergoing surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data. Interact Cardiovasc Thorac Surg. 2020;31:299–304.CrossRef
18.
go back to reference Kroese TE, Dijksterhuis WPM, van Rossum PSN, et al. Prognosis of interval distant metastases after neoadjuvant chemoradiotherapy for esophageal cancer. Ann Thorac Surg. 2021;S0003–4975(21):00306–14. Kroese TE, Dijksterhuis WPM, van Rossum PSN, et al. Prognosis of interval distant metastases after neoadjuvant chemoradiotherapy for esophageal cancer. Ann Thorac Surg. 2021;S0003–4975(21):00306–14.
19.
go back to reference Seesing MFJ, van der Veen A, Brenkman HJF, Gastroesophageal Metastasectomy Group, et al. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus. 2019;32:034. Seesing MFJ, van der Veen A, Brenkman HJF, Gastroesophageal Metastasectomy Group, et al. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus. 2019;32:034.
20.
go back to reference Matsubara T, Yamada K, Nakagawa A. Risk of second primary malignancy after esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:4336–41.CrossRef Matsubara T, Yamada K, Nakagawa A. Risk of second primary malignancy after esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:4336–41.CrossRef
21.
go back to reference van der Schaaf M, Rutegård M, Lagergren P. The influence of surgical factors on persisting symptoms 3 years after esophageal cancer surgery: a population-based study in Sweden. Ann Surg Oncol. 2013;20:1639–45.CrossRef van der Schaaf M, Rutegård M, Lagergren P. The influence of surgical factors on persisting symptoms 3 years after esophageal cancer surgery: a population-based study in Sweden. Ann Surg Oncol. 2013;20:1639–45.CrossRef
22.
go back to reference Schandl A, Johar A, Lagergren J, et al. Lymphadenectomy and health-related quality of life after oesophageal cancer surgery: a nationwide, population-based cohort study. BMJ Open. 2016;6:e012624.CrossRef Schandl A, Johar A, Lagergren J, et al. Lymphadenectomy and health-related quality of life after oesophageal cancer surgery: a nationwide, population-based cohort study. BMJ Open. 2016;6:e012624.CrossRef
23.
go back to reference Martin L, Lagergren P. Long-term weight change after oesophageal cancer surgery. Br J Surg. 2009;96:1308–14.CrossRef Martin L, Lagergren P. Long-term weight change after oesophageal cancer surgery. Br J Surg. 2009;96:1308–14.CrossRef
24.
go back to reference Schandl A, Lagergren J, Johar A, et al. Health-related quality of life 10 years after oesophageal cancer surgery. Eur J Cancer. 2016;69:43–50.CrossRef Schandl A, Lagergren J, Johar A, et al. Health-related quality of life 10 years after oesophageal cancer surgery. Eur J Cancer. 2016;69:43–50.CrossRef
25.
go back to reference Lv Y, Zhang J, Qiao L. Quality of life in patients with esophageal cancer receiving definitive chemoradiotherapy or esophagectomy. Mol Clin Oncol. 2014;2:870–4.CrossRef Lv Y, Zhang J, Qiao L. Quality of life in patients with esophageal cancer receiving definitive chemoradiotherapy or esophagectomy. Mol Clin Oncol. 2014;2:870–4.CrossRef
26.
go back to reference Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15:305–14.CrossRef Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15:305–14.CrossRef
27.
go back to reference Ito H, Itasaka S, Sakanaka K, et al. Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical method. J Radiat Res. 2017;58:106–13.CrossRef Ito H, Itasaka S, Sakanaka K, et al. Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical method. J Radiat Res. 2017;58:106–13.CrossRef
28.
go back to reference Wikman A, Ljung R, Johar A, et al. Psychiatric morbidity and survival after surgery for esophageal cancer: a population-based cohort study. J Clin Oncol. 2015;33:448–54.CrossRef Wikman A, Ljung R, Johar A, et al. Psychiatric morbidity and survival after surgery for esophageal cancer: a population-based cohort study. J Clin Oncol. 2015;33:448–54.CrossRef
29.
go back to reference Mantoan S, Cavallin F, Pinto E, et al. Long-term quality of life after esophagectomy with gastric pull-up. J Surg Oncol. 2018;117:970–6.CrossRef Mantoan S, Cavallin F, Pinto E, et al. Long-term quality of life after esophagectomy with gastric pull-up. J Surg Oncol. 2018;117:970–6.CrossRef
Metadata
Title
Nationwide survey of the follow-up practices for patients with esophageal carcinoma after radical treatment: historical changes and future perspectives in Japan
Authors
Tomonori Nakanoko
Masaru Morita
Yuichiro Nakashima
Mitsuhiko Ota
Masahiko Ikebe
Manabu Yamamoto
Eisuke Booka
Hiroya Takeuchi
Yuko Kitagawa
Hisahiro Matsubara
Yuichiro Doki
Yasushi Toh
Publication date
01-01-2022
Publisher
Springer Singapore
Published in
Esophagus / Issue 1/2022
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-021-00869-3

Other articles of this Issue 1/2022

Esophagus 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.